Zavicefta (ceftazidime–avibactam) | Dosering hos voksne

Kun for helsepersonell

Søk

Logg inn

Logg ut

Legemiddel

Terapiområde

Utforsk mer

Materiell

Video/podkast

Nyhetsbrev

Kontakt oss

Om Zavicefta

Virkningsmekanisme

Patogen dekning

Tidlig hensiktsmessig behandling

IDSA anbefaling

Økonomiske holdepunkter

Spørsmål og svar om ZAVICEFTA

Pasientprofiler

HAP/VAP pasient

cUTI pasient

cIAI pasient

Pediatriske pasienter

Spørsmål og svar - FAQs

Effekt

Real-world evidence

Effektdata

Spørsmål og svar om effekt

Sikkerhet

Sikkerhet hos voksne

Sikkerhet hos barn/ungdom

Spørsmål og svar om sikkerhet

Dosering

Dosering hos voksne

Dosering hos barn/ungdom

Spørsmål og svar om dosering

ZAVICEFTA (ceftazidime–avibactam) provides dosing options to treat paediatric patients aged 3 months to <18 years with consistent dosing across indications¹

Dosering hos barn/ungdom

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m² (refer to SmPC for full dosing information)^†‡§

Scroll left to view table

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m2 (refer to SmPC for full dosing information)^†‡§

Dosage adjustment is required for paediatric patients with renal impairment aged ≥2 years with CrCl* ≤50 mL/min/1.73 m^2:1

Scroll left to view table

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m2 (refer to SmPC for full dosing information)^†‡§

Dosage adjustment is also recommended in paediatric patients aged <2 years with CrCl* ≤50 mL/min/1.73 m^2:1

Scroll left to view table

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m2 (refer to SmPC for full dosing information)^†‡§

Watch this short video that outlines the recommended dosing and administration of ZAVICEFTA for paediatric patients and provides a short worked example of how to calculate the correct dose in a paediatric patient

Please refer to the full dosing table in the SmPC for more information.¹

Explore more

Safety and tolerability

Learn more about ZAVICEFTA’s safety and tolerability in adult and paediatric patients.

Footnotes:

^*CrCl estimated using the Schwartz bedside formula for paediatric patients aged 3 months and older.
^†The dose of ZAVICEFTA in patients with estimated CrCl ≤50 mL/min/1.73 m² should be adjusted according to recommended doses.
^‡For the treatment of cIAI and infections due to aerobic Gram-negative organisms in patients with LTO, ZAVICEFTA should be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the
infectious process.
^§Across all indications, ZAVICEFTA should be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
^¶The total treatment duration shown may include IV ZAVICEFTA followed by appropriate oral therapy.
^**There is limited experience with the use of ZAVICEFTA in paediatric patients aged 3 months to <6 months.
^††There is very limited experience with the use of ZAVICEFTA for more than 14 days.
^‡‡Dose recommendations are based on PK modelling.
^§§Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA (ceftazidime–avibactam) on haemodialysis days should occur after completion of haemodialysis.

Abbreviations:

cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end-stage renal disease HAP, hospital-acquired pneumonia; IV, intravenous; LTO, limited treatment options; PK, pharmacokinetics SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.

Reference:

ZAVICEFTA SPC

Preparatomtale

PP-ZVA-NOR-0141 Mai 2023

Dosering

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00

PP-BCP-NOR-0001 juni 2023

Du forlater nå PfizerPro.no

Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.